Telomir Pharmaceuticals (TELO) News
NASDAQ: TELOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TELO news summary
We found 2 recent headlines mentioning Telomir Pharmaceuticals (TELO): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. TELO is making an outsized move today, down 17.24% at $0.364, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Telomir Pharmaceuticals, Inc. Selects Linical to Support Phase 1/2 Clinical Trial of Telomir-Zn", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Telomir Pharmaceuticals headlines
- Telomir Pharmaceuticals, Inc. Selects Linical to Support Phase 1/2 Clinical Trial of Telomir-ZnTelomir Pharmaceuticals, Inc. has selected Linical, a global contract research organization, to support its U.S. Food and Drug Administration-cleared Phase 1/2 clinical trial evaluating Telomir-Zn in…Nasdaq
- Telomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast CancerTelomir selects Linical to advance FDA-cleared Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer, targeting Q1 2027 clinical initiation.GlobeNewswire